Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health’s rise from start-up to public telehealth leader is powered by one metric investors can’t ignore: subscriber retention across dermatology, mental-health and primary-care lines. That data lives deep inside each SEC filing.
Stock Titan surfaces exactly what matters. Our AI engine turns the dense language of a Hims & Hers Health annual report 10-K simplified into plain-English insights on fulfillment margins, privacy compliance costs and segment revenue. Need the latest Hims & Hers Health quarterly earnings report 10-Q filing? It arrives here in real time, alongside concise commentary that links prescription growth to cash-flow swings. Material developments—regulatory shifts, pharmacy partnerships, class-action updates—trigger a Hims & Hers Health 8-K material events explained snapshot within minutes.
Want to monitor management moves? Our alerts flag every Hims & Hers Health Form 4 insider transactions real-time so you can compare option exercises against marketing-spend disclosures. The page also answers common searches such as “Hims & Hers Health insider trading Form 4 transactions” and “Hims & Hers Health proxy statement executive compensation,” pairing raw documents with readable summaries.
- AI-powered digests that make understanding Hims & Hers Health SEC documents with AI straightforward
- Cross-links to Hims & Hers Health earnings report filing analysis for trend tracking
- Downloadable exhibits covering Hims & Hers Health executive stock transactions Form 4
Stop wading through 300 pages; let Stock Titan transform complex disclosures into investable clarity.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing discloses an insider’s intention to sell 250 Class A shares (estimated market value $16,110) on or after 1 Aug 2025 through Fidelity Brokerage on the NYSE. The notice also details recent insider activity: over the past three months the same individual, Michael Y. Chi, has already sold 69,802 Class A shares for gross proceeds of ≈$4.27 million. Outstanding Class A shares total 215.45 million, so the planned sale represents a negligible 0.0001% of shares outstanding, while the cumulative three-month sales equal roughly 0.03%.
The signer affirms he is unaware of any undisclosed material adverse information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No other financial metrics, guidance, or operational updates are provided; the filing is strictly a procedural notice under Rule 144.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Michael Y. Chi has filed a notice to sell 26,350 Class A shares through Fidelity Brokerage on or about 31 Jul 2025 on the NYSE. At the 07/30/25 market price used by the filer, the stake is valued at $1.77 million and represents roughly 0.012 % of the company’s 215.45 million shares outstanding.
The shares were acquired via four employee option grants dated 24 Feb 2022, 27 May 2021, 10 Aug 2022 and 01 Mar 2023, all exercised for cash on 31 Jul 2025. Over the past three months Chi has already disposed of 43,452 shares in five open-market transactions between 06 Jun 2025 and 24 Jul 2025, generating $2.51 million in gross proceeds.
No additional financial data, earnings guidance or company commentary is included in this notice. The filing merely discloses the planned sale under Rule 144 and affirms that the filer is not in possession of undisclosed material adverse information.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating that stockholder Soleil Boughton intends to sell 2,572 Class A shares through Fidelity Brokerage on or about 07/28/2025 on the NYSE. The proposed sale has an aggregate market value of $150,976.40, based on data supplied in the filing. Shares outstanding are listed at 215,453,899, so the contemplated sale represents roughly 0.0012 % of total Class A shares.
The shares to be sold were acquired via restricted-stock vesting on 06/15/2025 and are being sold for compensation purposes. The filer certifies possession of no undisclosed material adverse information.
Recent activity: Over the past three months, the same seller disposed of 22,871 shares across seven transactions, generating $1.18 million in gross proceeds. Transaction sizes ranged from 2,572 to 5,451 shares, signalling a pattern of periodic liquidations rather than a single block sale.
No other financial metrics, earnings data, or company-level events are disclosed in this notice.
The Form 144 filing indicates that an insider, Michael Y. Chi, plans to sell up to 2,100 Class A shares of Hims & Hers Health, Inc. (HIMS) through Fidelity Brokerage on or about 24 Jul 2025. At the prevailing price used in the form, the proposed sale is valued at $120,792. With 215,453,899 Class A shares outstanding, the transaction represents roughly 0.001 % of the public float.
Chi acquired the shares via an employee stock option granted 24 Feb 2022 and exercised for cash on 24 Jul 2025. The filing also discloses prior insider activity:
- 5100 shares sold 06 Jun 2025 for $285,600
- 5400 shares sold 10 Jun 2025 for $307,800
- 17,102 shares sold 17 Jun 2025 for $1,021,844.50
- 13,750 shares sold 23 Jul 2025 for $770,000
The notice affirms the seller is not aware of undisclosed adverse information. While continued insider selling may warrant monitoring, the volume remains immaterial relative to the company’s capitalization and is unlikely to affect trading dynamics on its own.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company’s 215,453,899 shares outstanding, implying minimal dilution or governance impact.
The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.
Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.
Hims & Hers Health (HIMS) has filed a Form 144 disclosing CEO Andrew Dudum’s intention to sell up to 125,335 Class A shares (≈ $6.21 million) through Fidelity Brokerage on or after 21 Jul 2025. The proposed block equals 0.06 % of the 215.5 million shares outstanding.
The notice also lists prior insider activity: entities tied to Dudum disposed of ≈ 463,000 shares between 28 Apr and 16 Jul 2025, generating roughly $26.9 million in gross proceeds. Individual sales ranged from 2,792 to 128,127 shares.
No operational or financial metrics accompany the filing; Form 144 only signals planned insider sales. Although the volume is small relative to float, continued CEO selling can pressure sentiment. Investors may watch for additional filings, confirmation of a 10b5-1 plan, or further ownership changes.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
